The dysregulation of the PGC-1a-TFAM signaling pathway is particularly notable in kidney tumors bearing FLCN mutations and in tumors originating from other organs with comparatively diminished FLCN expression levels. The gene discussed is FLCN; the disease is kidney neoplasm.